Improving the lives of people living with myasthenia gravis
Myasthenia gravis (MG) is a long-term auto-immune, neuromuscular disease associated with skeletal muscle weakness. It can affect the muscles of the eyes and face, resulting in vision, speech and swallowing difficulties.
At UCB, we are committed to developing meaningful solutions for people living with serious conditions, including MG. That is why we are pleased to support the Myasthenia Gravis Foundation of America (MGFA) National Conference (March 30-April 2) in Atlanta, Georgia – close to our US headquarters.
The MGFA is the only national volunteer health agency in the United States dedicated solely to the fight against myasthenia gravis. MGFA serves patients, their families and caregivers. The MGFA Patient Conference is a key platform for highlighting the impact of MG, in the US. It has played an important role in raising awareness, improving understanding, and highlighting the need for improved management of this chronic autoimmune condition.
As a patient-driven event, the MGFA Conference ensures patient voices are heard and that a holistic view is taken of the condition. As reflected in the conference program, MGFA highlights clinical matters facing patients as well as quality of life issues such as sleep and general wellbeing.
This is a chance for us to immerse ourselves in the largest MG patient meeting in the world. We are looking forward to working with the Foundation to ensure that we address the needs of those who could most benefit from our solutions. UCB intends to develop our partnership with MGFA through a number of future projects.
Additionally, one of our senior Medical Directors, Ali Bozorg, will share insights from UCB’s research on a potential future therapeutic option for MG and describe how we’re engaging with patients and patient advocates on a forthcoming phase III study designed to move this medicine closer to the patient.
Alongside the conference, many of our colleagues will also be participating in the National MG Walk on the morning of March 30 – an annual awareness-raising initiative organised by MGFA.
Together, based on insights and engagement with patients and carers, we aim to deliver solutions that expand treatment options – for myasthenia gravis and as well as other serious medical conditions – which can fundamentally transform patient lives.